AstraZeneca granted Neoprobe exclusive, worldwide rights to AZD4694 to detect Alzheimer's disease (AD)

AstraZeneca plc

U.K. / Large-Cap Biopharma (>=$50 billion)

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Neoprobe Corp.

U.S. / Medical Devices and Diagnostics

$234.5m on 12/16/2011 [market cap]

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced